These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
369 related items for PubMed ID: 20196847
21. Quantitative combination effects between sulforaphane and 3,3'-diindolylmethane on proliferation of human colon cancer cells in vitro. Pappa G, Strathmann J, Löwinger M, Bartsch H, Gerhäuser C. Carcinogenesis; 2007 Jul; 28(7):1471-7. PubMed ID: 17331956 [Abstract] [Full Text] [Related]
27. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression. Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, Odunsi K, Karpf AR. Oncotarget; 2015 Sep 29; 6(29):27613-27. PubMed ID: 26243836 [Abstract] [Full Text] [Related]
28. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis. Sinha S, Sharma S, Sharma A, Vora J, Shrivastava N. Phytomedicine; 2021 Apr 29; 84():153492. PubMed ID: 33640782 [Abstract] [Full Text] [Related]
29. Antitumor activity and expression profiles of genes induced by sulforaphane in human melanoma cells. Arcidiacono P, Ragonese F, Stabile A, Pistilli A, Kuligina E, Rende M, Bottoni U, Calvieri S, Crisanti A, Spaccapelo R. Eur J Nutr; 2018 Oct 29; 57(7):2547-2569. PubMed ID: 28864908 [Abstract] [Full Text] [Related]
30. Role of lipid peroxidation in cellular responses to D,L-sulforaphane, a promising cancer chemopreventive agent. Sharma R, Sharma A, Chaudhary P, Pearce V, Vatsyayan R, Singh SV, Awasthi S, Awasthi YC. Biochemistry; 2010 Apr 13; 49(14):3191-202. PubMed ID: 20205397 [Abstract] [Full Text] [Related]
31. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L, Kalli KR, Finn RS, Ginther C, Jones S, Velculescu VE, Riehle D, Cliby WA, Randolph S, Koehler M, Hartmann LC, Slamon DJ. Clin Cancer Res; 2011 Mar 15; 17(6):1591-602. PubMed ID: 21278246 [Abstract] [Full Text] [Related]
35. Bone morphogenetic protein-2 induces hypophosphorylation of Rb protein and repression of E2F in androgen-treated LNCaP human prostate cancer cells. Tomari K, Kumagai T, Shimizu T, Takeda K. Int J Mol Med; 2005 Feb 15; 15(2):253-8. PubMed ID: 15647840 [Abstract] [Full Text] [Related]
36. Optimizing combination therapy in prostate cancer: mechanistic insights into the synergistic effects of Paclitaxel and Sulforaphane-induced apoptosis. Habib TN, Altonsy MO, Ghanem SA, Salama MS, Hosny MA. BMC Mol Cell Biol; 2024 Mar 04; 25(1):5. PubMed ID: 38438917 [Abstract] [Full Text] [Related]
37. TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex. Madan E, Gogna R, Kuppusamy P, Bhatt M, Pati U, Mahdi AA. Br J Cancer; 2012 Jul 24; 107(3):516-26. PubMed ID: 22782351 [Abstract] [Full Text] [Related]
38. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine. Singh S, Davis R, Alamanda V, Pireddu R, Pernazza D, Sebti S, Lawrence N, Chellappan S. Mol Cancer Ther; 2010 Dec 24; 9(12):3330-41. PubMed ID: 21139044 [Abstract] [Full Text] [Related]
39. Mechanisms of cell cycle arrest by methylseleninic acid. Zhu Z, Jiang W, Ganther HE, Thompson HJ. Cancer Res; 2002 Jan 01; 62(1):156-64. PubMed ID: 11782373 [Abstract] [Full Text] [Related]
40. Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells. Chiao JW, Chung FL, Kancherla R, Ahmed T, Mittelman A, Conaway CC. Int J Oncol; 2002 Mar 01; 20(3):631-6. PubMed ID: 11836580 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]